PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

Paola Dongiovanni, Marica Meroni, Guido Baselli, Rosellina M. Mancina, Massimiliano Ruscica, Miriam Longo, Raffaela Rametta, Annalisa Cespiati, Serena Pelusi, Nicola Ferri, Valeria Ranzani, Valerio Nobili, Jussi Pihlajamaki, Anna Ludovica Fracanzani, Sara Badiali, Salvatore Petta, Silvia Fargion, Stefano Romeo, Julia Kozlitina, Luca Valenti

Research output: Contribution to journalArticle

Abstract

Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease in the UKBBC. In the DHS, PCSK7 missense variants were associated with circulating lipids. PCSK7 was expressed in hepatocytes and its hepatic expression correlated with that of lipogenic genes (P < 0.05). The rs236918 C allele was associated with upregulation of a new �gintra-PCSK7�h long noncoding RNA predicted to interact with the protein, higher hepatic and circulating PCSK7 protein (P < 0.01), which correlated with triglycerides (P = 0.04). In HepG2 cells, PCSK7 deletion reduced lipogenesis, fat accumulation, inflammation, transforming growth factor β pathway activation, and fibrogenesis. In conclusion, PCSK7 gene variation is associated with dyslipidemia and more severe liver disease in high risk individuals, likely by modulating PCSK7 expression/ activity.

Original languageEnglish (US)
Pages (from-to)1144-1153
Number of pages10
JournalJournal of lipid research
Volume60
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Proprotein Convertases
Subtilisin
Dyslipidemias
Liver
Genes
Inflammation
Biopsy
Liver Diseases
Triglycerides
Iron
Alleles
Long Noncoding RNA
Lipids
Non-alcoholic Fatty Liver Disease
Lipogenesis
Iron Overload
Hep G2 Cells
Transforming Growth Factors
Transaminases
Hypercholesterolemia

Keywords

  • Genes in lipid dysfunction
  • Genetics
  • Metabolic disease
  • Nonalcoholic fatty liver disease
  • Proprotein convertase subtilisin/kexin type 7

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

Dongiovanni, P., Meroni, M., Baselli, G., Mancina, R. M., Ruscica, M., Longo, M., ... Valenti, L. (2019). PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of lipid research, 60(6), 1144-1153. https://doi.org/10.1194/jlr.P090449

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. / Dongiovanni, Paola; Meroni, Marica; Baselli, Guido; Mancina, Rosellina M.; Ruscica, Massimiliano; Longo, Miriam; Rametta, Raffaela; Cespiati, Annalisa; Pelusi, Serena; Ferri, Nicola; Ranzani, Valeria; Nobili, Valerio; Pihlajamaki, Jussi; Fracanzani, Anna Ludovica; Badiali, Sara; Petta, Salvatore; Fargion, Silvia; Romeo, Stefano; Kozlitina, Julia; Valenti, Luca.

In: Journal of lipid research, Vol. 60, No. 6, 01.01.2019, p. 1144-1153.

Research output: Contribution to journalArticle

Dongiovanni, P, Meroni, M, Baselli, G, Mancina, RM, Ruscica, M, Longo, M, Rametta, R, Cespiati, A, Pelusi, S, Ferri, N, Ranzani, V, Nobili, V, Pihlajamaki, J, Fracanzani, AL, Badiali, S, Petta, S, Fargion, S, Romeo, S, Kozlitina, J & Valenti, L 2019, 'PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients', Journal of lipid research, vol. 60, no. 6, pp. 1144-1153. https://doi.org/10.1194/jlr.P090449
Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of lipid research. 2019 Jan 1;60(6):1144-1153. https://doi.org/10.1194/jlr.P090449
Dongiovanni, Paola ; Meroni, Marica ; Baselli, Guido ; Mancina, Rosellina M. ; Ruscica, Massimiliano ; Longo, Miriam ; Rametta, Raffaela ; Cespiati, Annalisa ; Pelusi, Serena ; Ferri, Nicola ; Ranzani, Valeria ; Nobili, Valerio ; Pihlajamaki, Jussi ; Fracanzani, Anna Ludovica ; Badiali, Sara ; Petta, Salvatore ; Fargion, Silvia ; Romeo, Stefano ; Kozlitina, Julia ; Valenti, Luca. / PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. In: Journal of lipid research. 2019 ; Vol. 60, No. 6. pp. 1144-1153.
@article{fe6aff0e5ff849919051a3152ce422ab,
title = "PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients",
abstract = "Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease in the UKBBC. In the DHS, PCSK7 missense variants were associated with circulating lipids. PCSK7 was expressed in hepatocytes and its hepatic expression correlated with that of lipogenic genes (P < 0.05). The rs236918 C allele was associated with upregulation of a new �gintra-PCSK7�h long noncoding RNA predicted to interact with the protein, higher hepatic and circulating PCSK7 protein (P < 0.01), which correlated with triglycerides (P = 0.04). In HepG2 cells, PCSK7 deletion reduced lipogenesis, fat accumulation, inflammation, transforming growth factor β pathway activation, and fibrogenesis. In conclusion, PCSK7 gene variation is associated with dyslipidemia and more severe liver disease in high risk individuals, likely by modulating PCSK7 expression/ activity.",
keywords = "Genes in lipid dysfunction, Genetics, Metabolic disease, Nonalcoholic fatty liver disease, Proprotein convertase subtilisin/kexin type 7",
author = "Paola Dongiovanni and Marica Meroni and Guido Baselli and Mancina, {Rosellina M.} and Massimiliano Ruscica and Miriam Longo and Raffaela Rametta and Annalisa Cespiati and Serena Pelusi and Nicola Ferri and Valeria Ranzani and Valerio Nobili and Jussi Pihlajamaki and Fracanzani, {Anna Ludovica} and Sara Badiali and Salvatore Petta and Silvia Fargion and Stefano Romeo and Julia Kozlitina and Luca Valenti",
year = "2019",
month = "1",
day = "1",
doi = "10.1194/jlr.P090449",
language = "English (US)",
volume = "60",
pages = "1144--1153",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

AU - Dongiovanni, Paola

AU - Meroni, Marica

AU - Baselli, Guido

AU - Mancina, Rosellina M.

AU - Ruscica, Massimiliano

AU - Longo, Miriam

AU - Rametta, Raffaela

AU - Cespiati, Annalisa

AU - Pelusi, Serena

AU - Ferri, Nicola

AU - Ranzani, Valeria

AU - Nobili, Valerio

AU - Pihlajamaki, Jussi

AU - Fracanzani, Anna Ludovica

AU - Badiali, Sara

AU - Petta, Salvatore

AU - Fargion, Silvia

AU - Romeo, Stefano

AU - Kozlitina, Julia

AU - Valenti, Luca

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease in the UKBBC. In the DHS, PCSK7 missense variants were associated with circulating lipids. PCSK7 was expressed in hepatocytes and its hepatic expression correlated with that of lipogenic genes (P < 0.05). The rs236918 C allele was associated with upregulation of a new �gintra-PCSK7�h long noncoding RNA predicted to interact with the protein, higher hepatic and circulating PCSK7 protein (P < 0.01), which correlated with triglycerides (P = 0.04). In HepG2 cells, PCSK7 deletion reduced lipogenesis, fat accumulation, inflammation, transforming growth factor β pathway activation, and fibrogenesis. In conclusion, PCSK7 gene variation is associated with dyslipidemia and more severe liver disease in high risk individuals, likely by modulating PCSK7 expression/ activity.

AB - Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease in the UKBBC. In the DHS, PCSK7 missense variants were associated with circulating lipids. PCSK7 was expressed in hepatocytes and its hepatic expression correlated with that of lipogenic genes (P < 0.05). The rs236918 C allele was associated with upregulation of a new �gintra-PCSK7�h long noncoding RNA predicted to interact with the protein, higher hepatic and circulating PCSK7 protein (P < 0.01), which correlated with triglycerides (P = 0.04). In HepG2 cells, PCSK7 deletion reduced lipogenesis, fat accumulation, inflammation, transforming growth factor β pathway activation, and fibrogenesis. In conclusion, PCSK7 gene variation is associated with dyslipidemia and more severe liver disease in high risk individuals, likely by modulating PCSK7 expression/ activity.

KW - Genes in lipid dysfunction

KW - Genetics

KW - Metabolic disease

KW - Nonalcoholic fatty liver disease

KW - Proprotein convertase subtilisin/kexin type 7

UR - http://www.scopus.com/inward/record.url?scp=85067055093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067055093&partnerID=8YFLogxK

U2 - 10.1194/jlr.P090449

DO - 10.1194/jlr.P090449

M3 - Article

VL - 60

SP - 1144

EP - 1153

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 6

ER -